Aldebaran Capital LLC Acquires Shares of 45,572 OnKure Therapeutics (NASDAQ:OKUR)

Aldebaran Capital LLC bought a new position in OnKure Therapeutics (NASDAQ:OKUR) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 45,572 shares of the company’s stock, valued at approximately $392,000. Aldebaran Capital LLC owned approximately 1.36% of OnKure Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC bought a new position in OnKure Therapeutics in the 4th quarter valued at approximately $659,000. Aisling Capital Management LP bought a new position in shares of OnKure Therapeutics during the fourth quarter valued at $762,000. Finally, Highbridge Capital Management LLC bought a new position in shares of OnKure Therapeutics during the fourth quarter valued at $3,438,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

OnKure Therapeutics Stock Down 5.8 %

Shares of NASDAQ:OKUR opened at $3.89 on Friday. The company has a market cap of $52.27 million, a PE ratio of -0.32 and a beta of 0.28. The business has a 50 day simple moving average of $5.15. OnKure Therapeutics has a twelve month low of $3.82 and a twelve month high of $20.00.

OnKure Therapeutics (NASDAQ:OKUR) last issued its quarterly earnings results on Monday, March 10th. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.51). Equities analysts forecast that OnKure Therapeutics will post -4.05 earnings per share for the current year.

Wall Street Analysts Forecast Growth

OKUR has been the subject of a number of recent analyst reports. Leerink Partnrs raised OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Leerink Partners assumed coverage on shares of OnKure Therapeutics in a research report on Thursday, December 5th. They set an “outperform” rating and a $33.00 price objective on the stock. Oppenheimer cut their target price on shares of OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a research report on Tuesday, March 11th. Finally, HC Wainwright decreased their target price on shares of OnKure Therapeutics from $40.00 to $34.00 and set a “buy” rating for the company in a research note on Tuesday, March 18th. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, OnKure Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $32.33.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.